NAD metabolism fuels human and mouse intestinal inflammation.

Related Articles NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2017 Sep 06;: Authors: Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, Wieser V, Pfister A, Moser P, Hermann-Kleiter N, Baier G, Oberacher H, Tilg H, Moschen AR Abstract OBJECTIVE: Nicotinamide phosphoribosyltransferase (NAMPT, also referred to as pre-B cell colony-enhancing factor or visfatin) is critically required for the maintenance of cellular nicotinamide adenine dinucleotide (NAD) supply catalysing the rate-limiting step of the NAD salvage pathway. NAMPT is strongly upregulated in inflammation including IBD and counteracts…

Read More

Early intervention in Crohn’s disease: towards disease modification trials.

Related Articles Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017 Sep 05;: Authors: Danese S, Fiorino G, Peyrin-Biroulet L Abstract Crohn’s disease (CD) is a chronic progressive destructive inflammatory bowel disease. As in rheumatoid arthritis, there is increasing evidence that early treatment initiation with disease-modifying agents, such as biological drugs, may lead to complete disease control, prevention of disease progression thus protecting against irreversible damage and restoration of normal quality of life. Data from randomised clinical trials with immunosuppressants and biologics suggest that treating patients with a…

Read More

Microbiomarkers in inflammatory bowel diseases: caveats come with caviar.

Related Articles Microbiomarkers in inflammatory bowel diseases: caveats come with caviar. Gut. 2017 Jul 21;: Authors: Sommer F, Rühlemann MC, Bang C, Höppner M, Rehman A, Kaleta C, Schmitt-Kopplin P, Dempfle A, Weidinger S, Ellinghaus E, Krauss-Etschmann S, Schmidt-Arras D, Aden K, Schulte D, Ellinghaus D, Schreiber S, Tholey A, Rupp J, Laudes M, Baines JF, Rosenstiel P, Franke A PMID: 28733278 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28733278?dopt=Abstract

Read More

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.

Related Articles Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial. Gut. 2017 Jul 11;: Authors: Bisschops R, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G Abstract BACKGROUND: Patients with long-standing UC have an increased risk for the development of colonic neoplastic lesions. Chromoendoscopy (CE) has been proven to enhance neoplasia detection while the role of virtual chromoendoscopy (VC) is still to be defined. OBJECTIVE: To compare the performance…

Read More

Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.

Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut. 2017 Jun 24;: Authors: Kirchgesner J, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M, BERENICE study group Abstract OBJECTIVE: Magnitude and independent drivers of the risk of acute arterial events in IBD are still unclear. We addressed this question in patients with IBD compared with the general population at a nationwide level. DESIGN: Using the French National Hospital Discharge Database from 2008 to 2013, all patients aged 15 years…

Read More

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.

Related Articles Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2017 Apr 27;: Authors: Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A Abstract OBJECTIVE: To evaluate the clinical relevance of antidrug antibodies (ADAs) measured using a drug-tolerant assay in a post hoc analysis of the Trough Concentration (TC) Adapted Infliximab Treatment (TAXIT) randomised controlled trial. DESIGN: ADA in serum samples (n=221) of 76 patients enrolled in TAXIT, who presented with an infliximab TC…

Read More

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner.

Related Articles Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut. 2017 Apr 20;: Authors: Trivedi PJ, Tickle J, Vesterhus MN, Eddowes PJ, Bruns T, Vainio J, Parker R, Smith D, Liaskou E, Thorbjørnsen LW, Hirschfield GM, Auvinen K, Hubscher SG, Salmi M, Adams DH, Weston CJ Abstract OBJECTIVE: Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of IBD. This clinical association is linked pathologically to the recruitment of mucosal T…

Read More

BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.

Related Articles BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis. Gut. 2017 May;66(5):852-862 Authors: Parang B, Kaz AM, Barrett CW, Short SP, Ning W, Keating CE, Mittal MK, Naik RD, Washington MK, Revetta FL, Smith JJ, Chen X, Wilson KT, Brand T, Bader DM, Tansey WP, Chen R, Brentnall TA, Grady WM, Williams CS Abstract OBJECTIVE: Blood vessel epicardial substance (BVES) is a tight junction-associated protein that regulates epithelial-mesenchymal states and is underexpressed in epithelial malignancy. However, the functional impact of BVES loss on tumourigenesis is unknown. Here…

Read More
<< Go Back